In November 2025 the Food and Drug Administration (FDA) removed the boxed warning from menopausal hormone therapy (MHT) products. This regulatory action represents a notable shift in the presentation of product risks and benefits and reflects reassessment of the evidence that has accumulated since the Women's Health Initiative (WHI) randomized trials first influenced labeling and clinical practice.
The article summarized here situates the FDA action as an outcome of approximately 20 years of evolving evidence and regulatory review. The source notes the FDA press release dated November 10, 2025 as part of the documentation for this change.
The removal of the boxed warning is described as reflecting two decades of evidence-building since the original WHI publications. The WHI randomized controlled trial is cited in the article's references as the foundational study that initially altered perceptions of the safety profile of estrogen-plus-progestin therapy.
Subsequent large-scale and longer-term follow-up studies, narrative reviews, and contemporary analyses have informed a reassessment of risks and benefits. The article cites reviews and commentaries published in 2026 that discuss updated labeling and contemporary evidence on MHT outcomes. Specific study results, quantitative risk estimates, or meta-analytic findings were not reported in the abstract; readers are directed to the full article and its reference list for detailed data.
The source states that the article clarifies current indications and contraindications for MHT in light of the FDA's labeling change. While the abstract confirms that indications, contraindications, and the regulatory rationale are reviewed, the abstract does not list the specific clinical indications or absolute contraindications.
To obtain precise lists of indications (for example, management of vasomotor symptoms, prevention of osteoporosis for specific patient groups, or other uses) and contraindications, clinicians should consult the full text of the article and the updated labeling information from the FDA.
The labeling change has practical implications for nursing practice. The article emphasizes how the revision affects how clinicians and patients understand the risk–benefit profile of MHT and highlights the role of nurses in interpreting these changes for patients.
Key nursing implications noted in the source include:
The abstract indicates that this regulatory inflection point will influence both clinician and patient perceptions but does not provide scripted counseling language or detailed educational protocols within the abstract itself.
According to the article summary, practical guidance is provided for nurses counseling patients about menopause management options. The guidance is framed around the updated regulatory context and contemporary evidence, with an emphasis on translating the change in boxed warning status into clinical conversations.
The abstract does not reproduce specific counseling checklists, algorithms, or stepwise management plans. For operational tools—such as recommended screening questions, risk assessment checklists, monitoring schedules, or patient handouts—nurses should review the full article and the primary sources cited there, including the FDA press release and contemporary reviews of MHT.
The article includes references that document the historical and contemporary evidence base. Notable cited items in the abstract and reference list include the original WHI JAMA publication (2002), longer-term WHI follow-up analyses (2013), the FDA press announcement (November 10, 2025), and recent 2026 commentaries and reviews discussing updated labeling and the regulatory context.
The source abstract also points readers to multiple recent reviews and analyses published in 2026 that discuss updated labeling, cardiovascular risk considerations, and narrative overviews of contemporary evidence on MHT. For practice-ready detail, the full-text article and the primary sources it cites should be consulted.
If you need specific clinical tools (e.g., contraindication lists, patient education scripts, monitoring intervals), I can extract them from the full article or the FDA label—please provide the full text or permission to access those documents. As a reminder, the abstract itself confirms the scope of the review and its intentions but does not contain the granular operational details needed for protocol development.